Drug Uses

Ranitidine HCL is used for the treatment of active duodenal ulcer or for maintenance therapy for duodenal ulcer.

How Taken

Take Ranitidine HCL 150 mg tablets twice daily or 300 mg tablets once daily depending on how is most convenient for you. It is recommended that you take Ranitidine HCL before bedtime. Take each dose with a full glass of water.

Warnings/Precautions

If you are breast-feeding, talk to your doctor before taking Ranitidine HCL. Ranitidine HCL is secreted in human milk. Do not stop taking ranitidine without first talking to your doctor.

Missed Dose

If you miss a dose, use it as soon as you remember. If it is near the time of the next dose, skip the missed dose and resume your usual dosing schedule. Do not double the dose to catch up.

Possible Side Effects

The possible side effects that may occur during treatment with Ranitidine HCT are: constipation, diarrhea, nausea/vomiting, abdominal discomfort/pain, headache.

Storage

Store at controlled room temperature 15°-30°C (59°-86°F) in a dry place. Protect from light. Keep out of the reach of children.

Overdose

When overdosage occurs unabsorbed material has to be removed from your gastrointestinal tract. Seek emergency medical attention.

More Information

There are no restrictions on food, beverages, or activity while taking Ranitidine HCL, unless otherwise directed by your doctor.

Disclaimer

This drug information is for your information purposes only, it is not intended that this information covers all uses, directions, drug interactions, precautions, or adverse effects of your medication. This is only general information, and should not be relied on for any purpose. It should not be construed as containing specific instructions for any particular patient. We disclaim all responsibility for the accuracy and reliability of this information, and/or any consequences arising from the use of this information, including damage or adverse consequences to persons or property, however such damages or consequences arise. No warranty, either expressed or implied, is made in regards to this information.

Other info about Ranitidine-hcl at Wikipedia.org and other resources:

Chemically modified attapulgite with asparagine for selective solid-phase extraction and preconcentration of Fe(III) from environmental samples.
Authors: Zang Z, Li Z, Zhang L, Li R, Hu Z, Chang X, Cui Y A new method that utilizes asparagine modified attapulgite as a solid phase extractant has been developed for preconcentration of trace Fe(III) prior to the measurement by inductively coupled plasma optical emission spectrometry. Characterization of the surface modification was performed on the basis of Fourier transform infrared spectra. The separation/preconcentration conditions of the analyte were investigated, including the pH value, the shaking time, the sample fl ow rate and volume, the elution condition and the interfering ions. At pH 4, the new adsorbent had relatively high capacity and enrichment factor compared to other methods reported so far. The adsorbed Fe(III) was quantitatively eluted by 2mL of 0.5molL(-1) HCl. ...

Acura Pharmaceuticals And King Pharmaceuticals Announce Positive Top Line Results Of A Clinical Study Assessing Relative Abuse Potential
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) and King Pharmaceuticals, Inc. (NYSE: KG) today announced top-line results from Study AP-ADF-114 ("Study 114") titled "A Randomized, Double-Blind, Placebo- and Active-Controlled Study to Assess the Relative Abuse Potential of Acurox® (oxycodone HCl and niacin) Tablets in Non-Dependent Recreational Opioid Users." Study 114 top-line results demonstrate that two different potentially abused excess oral doses of Acurox® Tablets are significantly disliked compared to equivalent excess oral doses of oxycodone HCl tablets alone (without niacin)... (Source: Health News from Medical News Today)

Acura Pharmaceuticals And King Pharmaceuticals Announce Positive Top Line Results Of A Clinical Study Assessing Relative Abuse Potential
Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) and King Pharmaceuticals, Inc. (NYSE: KG) today announced top-line results from Study AP-ADF-114 ("Study 114") titled "A Randomized, Double-Blind, Placebo- and Active-Controlled Study to Assess the Relative Abuse Potential of Acurox® (oxycodone HCl and niacin) Tablets in Non-Dependent Recreational Opioid Users... (Source: Alcohol / Addiction / Illegal Drugs News From Medical News Today)

Xylocaine MPF Sterile Solution (Lidocaine HCl Sterile Solution) - updated on RxList
Xylocaine MPF Sterile Solution (Lidocaine HCl Sterile Solution) drug description - FDA approved labeling for prescription drugs and medications at RxList (Source: RxList - New and Updated Drug Monographs)

Naropin (Ropivacaine Hcl) - updated on RxList
Naropin (Ropivacaine Hcl) drug description - FDA approved labeling for prescription drugs and medications at RxList (Source: RxList - New and Updated Drug Monographs)